Posology : מינונים

3 DOSAGE AND ADMINISTRATION

3.1 Schizophrenia
Adults
The recommended starting and target dose for ARIPLY is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals. ARIPLY has been systematically evaluated and shown to be effective in a dose range of 10 to 30 mg/day, when administered as the tablet formulation; however, doses higher than 10 or 15 mg/day were not more effective than 10 or 15 mg/day. Dosage increases should generally not be made before 2 weeks, the time needed to achieve steady- state [see Clinical Studies (15.1)].
Maintenance Treatment: Maintenance of efficacy in schizophrenia was demonstrated in a trial involving patients with schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer. These patients were discontinued from those medications and randomized to either ARIPLY 15 mg/day or placebo, and observed for relapse [see Clinical Studies (15.1)]. Patients should be periodically reassessed to determine the continued need for maintenance treatment.
Adolescents
The recommended target dose of ARIPLY is 10 mg/day. Aripiprazole was studied in adolescent patients 13 to 17 years of age with schizophrenia at daily doses of 10 and 30 mg. The starting daily dose of the tablet formulation in these patients was 2 mg, which was titrated to 5 mg after 2 days and to the target dose of 10 mg after 2 additional days. Subsequent dose increases should be administered in 5 mg increments. The 30 mg/day dose was not shown to be more efficacious than the 10 mg/day dose. ARIPLY can be administered without regard to meals [see Clinical Studies (15.1)]. Patients should be periodically reassessed to determine the need for maintenance treatment.
Switching from Other Antipsychotics
There are no systematically collected data to specifically address switching patients with schizophrenia from other antipsychotics to ARIPLY or concerning concomitant administration with other antipsychotics. While immediate discontinuation of the previous antipsychotic treatment may be acceptable for some patients with schizophrenia, more gradual discontinuation may be most appropriate for others. In all cases, the period of overlapping antipsychotic administration should be minimized.

3.2 Bipolar I Disorder
Acute Treatment of Manic and Mixed Episodes
Adults: The recommended starting dose in adults is 15 mg given once daily as monotherapy and 10 mg to 15 mg given once daily as adjunctive therapy with lithium or valproate. ARIPLY can be given without regard to meals. The recommended target dose of ARIPLY is 15 mg/day, as monotherapy or as adjunctive therapy with lithium or valproate. The dose may be increased to 30 mg/day based on clinical response. The safety of doses above 30 mg/day has not been evaluated in clinical trials.
Pediatrics: The recommended starting dose in pediatric patients (10 to 17 years) as monotherapy is 2 mg/day, with titration to 5 mg/day after 2 days, and a target dose of 10 mg/day after 2 additional days. Recommended dosing as adjunctive therapy to lithium or valproate is the same. Subsequent dose increases, if needed, should be administered in 5 mg/day increments. ARIPLY can be given without regard to meals [see Clinical Studies (15.2)].

3.3 Adjunctive Treatment of Major Depressive Disorder
Adults
The recommended starting dose for ARIPLY as adjunctive treatment for patients already taking an antidepressant is 2 to 5 mg/day. The recommended dosage range is 2 to 15 mg/day. Dosage adjustments of up to 5 mg/day should occur gradually, at intervals of no less than 1 week [see Clinical Studies (15.3)]. Patients should be periodically reassessed to determine the continued need for maintenance treatment.

3.4 Irritability Associated with Autistic Disorder
Pediatric Patients (6 to 17 years)
The recommended dosage range for the treatment of pediatric patients with irritability associated with autistic disorder is 5 to 15 mg/day.
Dosing should be initiated at 2 mg/day. The dose should be increased to 5 mg/day, with subsequent increases to 10 or 15 mg/day if needed. Dose adjustments of up to 5 mg/day should occur gradually, at intervals of no less than 1 week [see Clinical Studies (15.4)]. Patients should be periodically reassessed to determine the continued need for maintenance treatment.


3.5 Dosage Adjustments for Cytochrome P450 Considerations
Dosage adjustments are recommended in patients who are known CYP2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors or strong CYP3A4 inducers (see Table 1). When the coadministered drug is withdrawn from the combination therapy, ARIPIPRAZOLE dosage should then be adjusted to its original level. When the coadministered CYP3A4 inducer is withdrawn, ARIPIPRAZOLE dosage should be reduced to the original level over 1 to 2 weeks. Patients who may be receiving a combination of strong, moderate, and weak inhibitors of CYP3A4 and CYP2D6 (e.g., a strong CYP3A4 inhibitor and a moderate CYP2D6 inhibitor or a moderate CYP3A4 inhibitor with a moderate CYP2D6 inhibitor), the dosing may be reduced to one-quarter (25%) of the usual dose initially and then adjusted to achieve a favorable clinical response.


Table 1: Dose Adjustments for Aripiprazole in Patients who are known CYP2D6 Poor Metabolizers and Patients Taking Concomitant CYP2D6 Inhibitors, 3A4 Inhibitors, and/or CYP3A4 Inducers Dosage Adjustments
Factors for ARIPIPRAZOLE

Administer half of
Known CYP2D6 Poor Metabolizers usual dose

Known CYP2D6 Poor Metabolizers taking concomitant strong CYP3A4         Administer a quarter of inhibitors (e.g., itraconazole,          usual dose clarithromycin)

Strong CYP2D6 (e.g., quinidine,
fluoxetine, paroxetine) or CYP3A4        Administer half of inhibitors (e.g., itraconazole,          usual dose clarithromycin)

Strong CYP2D6 and CYP3A4                 Administer a quarter of inhibitors                               usual dose

Strong CYP3A4 inducers (e.g.,            Double usual dose over carbamazepine, rifampin)                 1 to 2 weeks


When adjunctive ARIPLY is administered to patients with major depressive disorder, ARIPLY should be administered without dosage adjustment as specified in Dosage and Administration (3.3).


4 DOSAGE FORMS
Ariply 5 drug product is presented as round, biconvex, pale- yellow tablet with breakline on one side.
Ariply 10;15 and 30 drug product is presented as round, biconvex, pale yellow tablet.